News

For neurologists working with patients with Alzheimer’s disease, the road to actual treatment options has been long and paved with setbacks.

But that is changing for some patients. The Food and Drug Administration recently granted full approval to Leqembi® (lecanemab), the first disease-modifying treatment fully approved for patients in the early stages of Alzheimer’s disease. The development of this new drug offers hope to patients and may have lasting impacts on how physicians approach treatment.

Winter’s frigid temperatures often drive us to gather indoors with family and friends, increasing the risk of developing a respiratory illness. The lessons learned from managing COVID-19 help with other winter illnesses such as colds, influenza, and respiratory syncytial virus (RSV), which can significantly affect young children. Medical experts remind us to: